201 related articles for article (PubMed ID: 28159621)
1. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases.
Giacomelli C; Daniele S; Martini C
Biochem Pharmacol; 2017 May; 131():1-15. PubMed ID: 28159621
[TBL] [Abstract][Full Text] [Related]
2. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
3. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
4. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.
Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B
Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196
[TBL] [Abstract][Full Text] [Related]
5. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
Takeda A; Mallory M; Sundsmo M; Honer W; Hansen L; Masliah E
Am J Pathol; 1998 Feb; 152(2):367-72. PubMed ID: 9466562
[TBL] [Abstract][Full Text] [Related]
6. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
7. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
El-Agnaf OM; Irvine GB
J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
[TBL] [Abstract][Full Text] [Related]
8. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Lee VM; Giasson BI; Trojanowski JQ
Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
[TBL] [Abstract][Full Text] [Related]
9. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
10. Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Liu J; Mouradian MM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397040
[TBL] [Abstract][Full Text] [Related]
11. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
Windisch M; Hutter-Paier B; Schreiner E; Wronski R
J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
[TBL] [Abstract][Full Text] [Related]
12. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
[TBL] [Abstract][Full Text] [Related]
13. Protein aggregation and ER stress.
Ogen-Shtern N; Ben David T; Lederkremer GZ
Brain Res; 2016 Oct; 1648(Pt B):658-666. PubMed ID: 27037184
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein: its biological function and role in neurodegenerative diseases.
Kaplan B; Ratner V; Haas E
J Mol Neurosci; 2003 Apr; 20(2):83-92. PubMed ID: 12794302
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.
Poças GM; Branco-Santos J; Herrera F; Outeiro TF; Domingos PM
Hum Mol Genet; 2015 Apr; 24(7):1898-907. PubMed ID: 25452431
[TBL] [Abstract][Full Text] [Related]
16. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.
Sierks MR; Chatterjee G; McGraw C; Kasturirangan S; Schulz P; Prasad S
Integr Biol (Camb); 2011 Dec; 3(12):1188-96. PubMed ID: 22076255
[TBL] [Abstract][Full Text] [Related]
17. Initiation and synergistic fibrillization of tau and alpha-synuclein.
Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
19. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
[TBL] [Abstract][Full Text] [Related]
20. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives.
Lee SJ; Lim HS; Masliah E; Lee HJ
Neurosci Res; 2011 Aug; 70(4):339-48. PubMed ID: 21624403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
